A randomised clinical trial investigating the effect of pembrolizumab + pomadoline + dexamethasone versus pomadoline + dexamethasone in refractory or relapsed and refractory Multiple Myeloma (rrMM)
| Studied treatment | pembrolizumab, Pomalidomide and low-dose Dexamethasone |
| Control treatment | Pomalidomide and low-dose Dexamethasone |
| Patients | refractory or relapsed and refractory Multiple Myeloma (rrMM) |
| Group sizes | 125 / 124 |
| Blindness | open-design | Inclusion period | |
| Follow-up duration | 7.8 mo / 8.6 mo (median) | Centers | |
| Lost to FU | geographical localisation | ||
| Primary endpoint | Design | Parallel groups |
Comment: Due to interim data presented to the data monitoring committees (DMC), the U.S. Food and Drug Administration (FDA) halted the trials and required that all patients in the two trials be discontinued
All trials of pembrolizumab + pomadoline + dexamethasone
Appears in following systematic reviews:
-
About
-
Browse pathology
|
treatment
-
Site map
-
Credits
Made with in Lyon
-
Contact us
-
Privacy policy
-
